Dr. Penson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St Yaw 9
Hematology/Oncology
Boston, MA 02114Phone+1 617-724-5951Fax+1 617-724-6898
Summary
- Dr. Richard Penson is a medical oncologist in Boston, MA at the Massachusetts General Hospital. He received his medical degree from Bart's and has been in practice 30 years. He is a key opinion leader in gynecologic cancer.
Education & Training
Barts and The London SOM & DentClass of 1987, MBBS, MRCP MD
Certifications & Licensure
MA State Medical License 2004 - 2025
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) Start of enrollment: 2005 Jun 01
- GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer Start of enrollment: 2004 Dec 01
- Neuropathic Pain in Patients With Cancer Start of enrollment: 2006 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 20 citationsA phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesotheliomaC.W. Mulatero, Richard T. Penson, Demetris Papamichael, N.H. Gower, M.T. Evans
Lung Cancer. 2001-01-01 - 219 citationsCediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal ...Ursula A. Matulonis, Suzanne Berlin, Percy Ivy, Karin Tyburski, Carolyn N. Krasner
Journal of Clinical Oncology. 2009-11-20 - 122 citationsOlaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safetyUrsula A. Matulonis, Richard T. Penson, Susan M. Domchek, Bella Kaufman, Ronnie Shapira-Frommer
Annals of Oncology. 2016-06-01
Lectures
- Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 tr...2019 ASCO Annual Meeting - 6/1/2019
- Clinical trial in progress: A study of VB-111 combined with paclitaxel vs. paclitaxel for treatment of recurrent platinum-resistant ovarian cancer (OVAL, VB-111-701/GO...2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Other
- Clinical features, diagnosis, staging, and treatment of uterine carcinosarcomaPenson RT, Powell MA
http://www.uptodate.com/contents/clinical-features-diagnosis-staging-and-treatment-of-uterine-carcin
UpToDate, Wolters Kluwer Health - 2013-04-01 - Cisplatin nephrotoxicityPenson RT, Safar AM, Portilla D, Shannon ML
http://www.uptodate.com/contents/cisplatin-nephrotoxicity
UpToDate, Wolters Kluwer Health - 2012-08-13
Press Mentions
What’s Next for Immunotherapy in Ovarian Cancer After “Disappointing” VB-111 Results?August 8th, 2022- Olaparib Did Not Improve PFS2, OS in SOLO3 TrialMarch 19th, 2022
The 6th Biennial Meeting of the Asian Society of Gynecologic Oncology, October 10th to 12th, 2019July 3rd, 2020- Join now to see all
Professional Memberships
- Member
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
